Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland (NA, NA, NA, NA, NA, NA)
Received: 22 June 2022
Accepted: 23 July 2022
First Online: 18 August 2022
: Approval for each study was provided by the Independent Ethics Committee or Institutional Review Board of the study sites. The list of the IEC or IRB for each study has been provided in the Additional file InternalRef removed. The studies were conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Participants provided written informed consent prior to initiation of any study procedures.
: Not applicable.
: Christian Lampl received honoraria from Novartis for given lectures and his participation in Advisory Board Meetings.Victoria Krauss declares that they have no competing interests.Katharina Lehner declares that they have no competing interests.Mahan Chehrenama is an employee of, and holds stock in Amgen Inc.Zofia Maczynska is a former employee of Novartis.Jan Klatt is a former employee of, and holds stock in Novartis.Brett Loop was an employee of Amgen Inc., US at the time of study conduct.Brett Loop, Shannon Ritter and Josefin Snellman are employees of, and hold stocks in Novartis.